Can Voquezna Be Taken Twice Daily?
Yes, Voquezna (vonoprazan) is FDA-approved for twice-daily dosing specifically for H. pylori eradication therapy, but not for GERD or erosive esophagitis treatment, where once-daily dosing is standard. 1
FDA-Approved Twice-Daily Dosing Regimens
H. pylori Eradication
Triple therapy: Vonoprazan 20 mg twice daily (morning and evening, 12 hours apart) plus amoxicillin 1,000 mg twice daily plus clarithromycin 500 mg twice daily for 14 days 1
Dual therapy: Vonoprazan 20 mg twice daily (morning and evening) plus amoxicillin 1,000 mg three times daily for 14 days 1
These twice-daily regimens achieve eradication rates of approximately 92% for triple therapy and 90-95% for dual therapy, representing a 10-20% absolute advantage over PPI-based regimens 2
Dosing Adjustments for Twice-Daily Use
Renal impairment: For patients with eGFR ≥30 mL/min, use vonoprazan 20 mg twice daily; for eGFR <30 mL/min, twice-daily use is not recommended 1
Hepatic impairment: For Child-Pugh Class A, use vonoprazan 20 mg twice daily; for Child-Pugh Class B or C, twice-daily use is not recommended 1
Once-Daily Dosing for Acid-Related Disorders
Standard Indications
Healing erosive esophagitis: Vonoprazan 20 mg once daily for 8 weeks 1
Maintenance of healed erosive esophagitis: Vonoprazan 10 mg once daily for up to 6 months 1
Non-erosive GERD: Vonoprazan 10 mg once daily for 4 weeks 1
Clinical Positioning
Vonoprazan should not be used as first-line therapy for GERD or peptic ulcer disease; it is reserved for patients who fail twice-daily PPI therapy 3, 2
The American Gastroenterological Association recommends starting with standard PPI therapy, escalating to twice-daily PPI if inadequate response, and considering vonoprazan only after failure of twice-daily PPI therapy 3
Key Clinical Considerations
When Twice-Daily Dosing Is Appropriate
Only for H. pylori eradication: The twice-daily regimen is specifically designed to achieve superior eradication rates, particularly against clarithromycin-resistant strains (66-70% success vs 32% with PPIs) 2
Not for GERD management: There is no FDA-approved indication or clinical evidence supporting twice-daily vonoprazan for erosive esophagitis or GERD treatment 1
Common Pitfalls to Avoid
Do not prescribe twice-daily vonoprazan for refractory GERD—the approved dosing is 20 mg once daily for healing and 10 mg once daily for maintenance 3, 1
Do not use twice-daily dosing in patients with severe renal impairment (eGFR <30 mL/min) or moderate-to-severe hepatic impairment (Child-Pugh B/C), as safety and efficacy have not been established 1
Account for significantly higher cost compared to PPIs when prescribing vonoprazan, as it is markedly more expensive than both standard and double-dose PPIs 3, 2